Reproductive history and the risk of molecular breast cancer subtypes in a prospective study of Norwegian women

Cancer Causes and Control

Volumn 25, Issue 7, 2014, Pages 881-889

  Horn, Julie ^a,b   Opdahl, Signe ^a   Engstrøm, Monica J ^a   Romundstad, Pål R ^a   Tretli, Steinar ^a,c   Haugen, Olav A ^a   Bofin, Anna M ^a   Vatten, Lars J ^a   Åsvold, Bjørn Olav ^a,d  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b Levanger Hospital   (Norway)

^c CANCER REGISTRY OF NORWAY   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast cancer; Epidemiology; Molecular subtype; Reproductive factors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ARTICLE; BREAST CANCER; BREAST FEEDING; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER RISK; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; NORWAY; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPRODUCTIVE HISTORY; TUMOR INVASION; BREAST NEOPLASMS; EPIDEMIOLOGY; GENETICS; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TISSUE MICROARRAY;

ADULT; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; NORWAY; PROPORTIONAL HAZARDS MODELS; REPRODUCTIVE HISTORY; TISSUE ARRAY ANALYSIS;

EID: 84904547476     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-014-0388-0     Document Type: Article

References (34)

1. Collaborative Group on Hormonal Factors in Breast C (2002) Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360(9328):187-195. doi:10.1016/S0140-6736(02)09454-0
2. Kelsey JL, Gammon MD, John EM (1993) Reproductive factors and breast cancer. Epidemiol Rev 15(1):36-47 (Pubitemid 23269069)
3. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomark Prev 13(10):1558-1568 A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (Pubitemid 39331875)
4. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752. doi:10.1038/35021093
5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874. doi:10.1073/pnas.191367098 (Pubitemid 32878711)
6. Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, Marotti J, Connolly JL, Schnitt SJ, Collins LC (2012) Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat 131(1):159-167. doi:10.1007/s10549-011-1702-0
7. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123-139. doi:10.1007/s10549-007-9632-6 (Pubitemid 351538762)
8. Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, Li CI (2011) Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control CCC 22(3):399-405. doi:10.1007/s10552-010-9709-0
9. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, Kabat GC, Rohan TE, Li CI (2011) Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 103(6):470-477. doi:10.1093/jnci/djr030
10. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736-750. doi:10.1093/jnci/djp082
11. Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S (2010) American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 6(4):195-197. doi:10.1200/JOP.777003 American Society of Clinical Oncology
12. Engstrom MJ, Opdahl S, Hagen AI, Romundstad PR, Akslen LA, Haugen OA, Vatten LJ, Bofin AM (2013) Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat. doi:10.1007/s10549-013-2647-2
13. Kvale G, Heuch I (1987) A prospective study of reproductive factors and breast cancer. II. Age at first and last birth. Am J Epidemiol 126(5):842-850 (Pubitemid 17161308)
14. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van de Vijver MJ (2012) WHO classification of tumours of the breast. IARC, Lyon
15. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403-410
16. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE (2004) Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96(3):218-228 (Pubitemid 38263181)
17. Rosner B, Glynn RJ, Tamimi RM, Chen WY, Colditz GA, Willett WC, Hankinson SE (2013) Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. Am J Epidemiol 178(2):296-308. doi:10.1093/aje/kws457
18. Lunn M, McNeil D (1995) Applying Cox regression to competing risks. Biometrics 51(2):524-532
19. Bergsjø P (1984) Comments on the use of oestrogens 1979-83. In: Øydvin K (ed) Drug consumption in Norway. Norsk medisinaldepot, Oslo, pp 114-115
20. Hofvind S, Sakshaug S, Ursin G, Graff-Iversen S (2012) Breast cancer incidence trends in Norway-explained by hormone therapy or mammographic screening? Int J Cancer J Int du cancer 130(12):2930-2938. doi:10.1002/ijc.26280
21. Kalager M, Zelen M, Langmark F, Adami HO (2010) Effect of screening mammography on breast-cancer mortality in Norway. New England J Med 363(13):1203-1210. doi:10.1056/NEJMoa1000727
22. Hofvind S, Sorum R, Thoresen S (2008) Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program. Acta Oncol 47(2):225-231. doi:10.1080/02841860701518041
23. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res Off J Am Assoc Cancer Res 14(5):1368-1376. doi:10.1158/1078-0432.CCR-07-1658 (Pubitemid 351413917)
24. Strand C, Bak M, Borgquist S, Chebil G, Falck AK, Fjallskog ML, Grabau D, Hedenfalk I, Jirstrom K, Klintman M, Malmstrom P, Olsson H, Ryden L, Stal O, Bendahl PO, Ferno M (2013) The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naive women with N0/N1 primary breast cancer. SpringerPlus 2(1):111. doi:10.1186/2193-1801-2-111
25. Ma H, Bernstein L, Pike MC, Ursin G (2006) Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res BCR 8(4):R43. doi:10.1186/bcr1525
26. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Aittomaki K, Heikkila P, Blomqvist C, Lissowska J, Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K, Humphreys K, Darabi H, Liu J, Van 't Veer LJ, van Leeuwen FE, Andrulis IL, Glendon G, Knight JA, Mulligan AM, O'Malley FP, Weerasooriya N, John EM, Beckmann MW, Hartmann A, Weihbrecht SB, Wachter DL, Jud SM, Loehberg CR, Baglietto L, English DR, Giles GG, McLean CA, Severi G, Lambrechts D, Vandorpe T, Weltens C, Paridaens R, Smeets A, Neven P, Wildiers H, Wang X, Olson JE, Cafourek V, Fredericksen Z, Kosel M, Vachon C, Cramp HE, Connley D, Cross SS, Balasubramanian SP, Reed MW, Dork T, Bremer M, Meyer A, Karstens JH, Ay A, Park-Simon TW, Hillemanns P, Arias Perez JI, Menendez Rodriguez P, Zamora P, Benitez J, Ko YD, Fischer HP, Hamann U, Pesch B, Bruning T, Justenhoven C, Brauch H, Eccles DM, Tapper WJ, Gerty SM, Sawyer EJ, Tomlinson IP, Jones A, Kerin M, Miller N, McInerney N, Anton-Culver H, Ziogas A, Shen CY, Hsiung CN, Wu PE, Yang SL, Yu JC, Chen ST, Hsu GC, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Lindblom A, Margolin S, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Gorski B, Gronwald J, Hooning MJ, Hollestelle A, van den Ouweland AM, Jager A, Kriege M, Tilanus-Linthorst MM, Collee M, Wang-Gohrke S, Pylkas K, Jukkola-Vuorinen A, Mononen K, Grip M, Hirvikoski P, Winqvist R, Mannermaa A, Kosma VM, Kauppinen J, Kataja V, Auvinen P, Soini Y, Sironen R, Bojesen SE, Orsted DD, Kaur-Knudsen D, Flyger H, Nordestgaard BG, Holland H, Chenevix-Trench G, Manoukian S, Barile M, Radice P, Hankinson SE, Hunter DJ, Tamimi R, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gaborieau V, Devilee P, Huijts PE, Tollenaar RA, Seynaeve C, Dite GS, Apicella C, Hopper JL, Hammet F, Tsimiklis H, Smith LD, Southey MC, Humphreys MK, Easton D, Pharoah P, Sherman ME, Garcia-Closas M (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies. J Natl Cancer Inst 103(3):250-263. doi:10.1093/jnci/djq526
27. Palmer JR, Boggs DA, Wise LA, Ambrosone CB, Adams-Campbell LL, Rosenberg L (2011) Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. Cancer Epidemio Biomark Prev 20(9):1883-1891. doi:10.1158/1055-9965.EPI-11-0465 A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
28. Ursin G, Bernstein L, Lord SJ, Karim R, Deapen D, Press MF, Daling JR, Norman SA, Liff JM, Marchbanks PA, Folger SG, Simon MS, Strom BL, Burkman RT, Weiss LK, Spirtas R (2005) Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. Br J Cancer 93(3):364-371. doi:10.1038/sj.bjc.6602712 (Pubitemid 43080039)
29. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Garcia-Closas M (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomark Prev 16(3):439-443. doi:10.1158/1055-9965.EPI-06-0806 A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (Pubitemid 46548646)
30. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ (2009) Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res BCR 11(3):R31. doi:10.1186/bcr2261
31. Yang L, Jacobsen KH (2008) A systematic review of the association between breastfeeding and breast cancer. J Women's Health 17(10):1635-1645. doi:10.1089/jwh.2008.0917
32. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE (2013) Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. Breast Cancer Res Treat 137(2):579-587. doi:10.1007/s10549-012-2365-1
33. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI (2008) Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 113(7):1521-1526. doi:10.1002/cncr.23786
34. Huang WY, Newman B, Millikan RC, Conway K, Hulka BS, Schell MJ, Liu ET (2000) Risk of breast cancer according to the status of HER-2/neu oncogene amplification. Cancer Epidemiol Biomark Prev 9(1):65-71 A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology This study was funded by The Norwegian Cancer Society. (Pubitemid 30062911)